ERBB2 and breast carcinoma: Several reports on miRNA:miRNA interactions have studied these networks in the context of their response to chemotherapeutic agents, such as that to the Erb-B2 receptor tyrosine kinase 2 (ERBB2) inhibitor Trastuzumab in breast cancer (Cilek et al., 2017), cisplatin resistance in ovarian cancer (Wang et al., 2018b) or experimental anti-miRNA agents, like miR-34 (Ooi et al., 2017).